





CTCR Management Committee Meeting Minutes

Tuesday, January 11, 2023 - 9:00 am to 10:00am - Via Teams Attendees: Drs. G Bauman, A. Allan, E. Wong, G. DiMattia, J. Ronald, S. Mattonen, S. Penuela, A. Parysan and R. McClelland, K. Scott Regrets: P. Taylor Absent: B. Fleming

1. Welcome & Additions to Minutes

Glenn Bauman welcome the committee members and asked for any additions to the minutes. GSB congratulated Richard McClelland on his expanded role and asked if he would update the members of his new duties once they were more defined. **ACTION ITEM: KS to add RM to a future agenda.**

 Approval of Meeting Minutes – September 20, 2022 Approved at this time. Please send any corrections to GSB or KS.

3. Current Business

3.1 R & E Update: GSB reported that the R & E co-leads have engaged Dr. Sarah Psutka, a urologist (bladder/renal cancer) specialist to be this year's plenary speaker. Dr. Psutka will be joining us from Seattle Washington. The Foundation will be once again fundraising for the event and the organizing team will be starting with \$10K left-over from last year's event.

3.2 TIORG Update: John Ronald reported that the committee hosted a retreat on November 23 and saw about 40 attendees. Seven labs were able to present their research. The committee has decided to be more trainee focused and have dropped their monthly meetings. Committee will be hosting the 4th Annual Immuno-Oncology Symposium on Wednesday March 29 at UWO's Great Hall in the Somerville House. Call for abstracts will be sent out shortly and will send out invitations to London, Guelph, Windsor area. Dr. John Yoo will be invited to bring greetings on behalf of Schulich.

Discussion was held and suggestion was made to establish an immuno-oncology educational type training session(s). The field is very new and massive. The CTCR could host and its website could act as a repository for resources. These sessions would require a program instructor and a syllabus similar to Harvard's Medical School online <u>certificate</u> on HMX Pro Immunology. Their course is 10 weeks long. Total hours are 15 to 20 and cost is \$995US. The subject matter includes an Overview of Immunology, Basic Tumor Immunology, Checkpoint Blockade, CAR T and other Novel Therapies. No suggestion was made to have the course accredited but to act as an informational session. **ACTION ITEMS:** JR and SP to discuss with Dr. Saman Maleki. To add to future agenda.

3.3 CTCR Renewal: GSB reported that Dr. Dale Laird will be contacting 5 members of the management committee to interview them as part of the centre's renewal process. KS to prepare a one-page briefing note to send to the interviewees.

3.4 Research Trainee Observership's: GSB reported that the working document is on hold at this time due to overcrowding and lack of resources in the clinics. **ACTION ITEM: KS to table at a later meeting.**

3.5 OICR Visit: Yearly visit with OICR was a success and representatives were very pleased. The format allowed for more research teams to be invited as presentations were discouraged. This allowed for more open dialogue. OICR mentioned they felt the research community had evolved and noticed more collaboration between citywide researchers. A discussion was held and members asked if we could reach out to the OICR representatives to ask: (a) for a list of OICR facilities (b) which facilities could be accessed and how-to procedures (c) shared funding opportunities (d) method of interreacting with OICR representatives to **December 6 meeting attendees to gather feedback. GSB to discuss findings with OICR and KS to add to future agenda.**

3.6 Management Team: As the centre is in the renewal process, GSB suggested we move to a future meeting. **ACTION ITEM: KS to add to future agenda.**

4. New Business

4.1 Terry Fox Marathon of Hope Centre Network: During OICR's visit, it was mentioned that the Terry Fox Marathon of Hope Centre had received a federal grant to create a network of Canadian centres for research purposes. Currently, the priority project is to compile a pan-canadian cohort of cancer patients with comprehensive genomic and transcriptomic profiling along with clinical data. They are looking for 15,000 patient samples and are interested in collaborating with centres/investigators with existing biobanks and or prospective studies for biospecimen collection. Funding is available to participating groups to help offset the cost of generating and supplying the data. This initiative is a positive one for London especially for the recently formed genome group and for the clinical bioinformatics researchers. The genome group met on January 10 to discuss and a follow-up meeting of London investigators involved in biobanking activities is planned. **ACTION ITEM: slides to be added to minutes.**

4.2 Ovarian Cancer Seminar: On November 8, Fred Dick hosted a former trainee Dr. Charles Ishak who gave a talk and met with current trainees. These types of event are very inspiring for current trainees. Great networking opportunity for trainees, great experience for speaker, and great networking for speaker to meet with principal investigators. Discussion was held that these types of events are very inspiring to all. Suggestion made to sponsor more of these types of events and perhaps name it "CTCR's Homecoming Series". Event cost just under \$1,000. ACTION ITEM: GSB/KS to discuss moving forward once notified of centre's renewal.

4.3 CIHR – Research Consultation: Dr. Fei-Fei Liu, the newly installed Director, CIHR Cancer Research reached out to GSB and mentioned she would like to see more engagement with London researchers and would like to create a community outreach program. **ACTION ITEM: Dr. Liu will be setting a follow-up meeting to discuss a research community engagement plan.**

5. Next Meeting: May 2, 2023

Distribution: Drs. G. Bauman, A. Allan, E. Wong, G. DiMattia, J. Ronald, S. Mattonen, S. Penuela, A. Parsyan and P. Taylor, B. Fleming, R. McClelland

Sob

Kimberly Scott

Dr. Glenn Bauman, Director

Kimberly Scott, Coordinator